Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice

Abstract

Exosomes are nano-sized vesicles of endolysosomal origin, released by several cytotypes in physiological and pathological conditions. Tumor derived exosomes, interacting with other cells of the tumor microenvironment, modulate tumor progression, angiogenic switch, metastasis, and immune escape. Recently, extracellular vesicles were proposed as excellent biomarkers for disease monitoring and prognosis in cancer patients. Non-small cell lung cancer (NSCLC) has a poor 5-year survival rate due to the delay in the detection of the disease. The majority of patients are diagnosed in an advanced disease stage. Exosomes might be promising beneficial tools as biomarker candidates in the scenario of NSCLC, since they contain both, proteins and miRNAs. The clinical case reported in this manuscript is a proof of concept revealing that NSCLC exosomes and sorted miRNAs might constitute, in a near future, novel biomarkers. This review summarizes the role of exosomes in NSCLC, focusing on the importance of exosomal microRNAs in lung cancer diagnosis and prognosis.

Placental Growth Factor Mediates Crosstalk Between Lung Cancer Cells and Tumor-Associated Macrophages in Controlling Cancer Vascularization and Growth

“…Non-small cell lung cancer (NSCLC) is a prevalent malignant disease [1,2]. Effective prevention and treatment of NSCLC largely relies on a thorough understanding of the molecular mechanisms underlying the growth and invasion of NSCLCs, which requires the participation of cancer-related angiogenesis [3].…”

Natural Compounds: Molecular Weapons against Leukemia’s

“…Moreover, exosomes containing miR-21 and released by CML cells treated with curcumin were able to modulate the endothelial barrier organization and attenuated the angiogenic phenotype. These data suggest that curcumin could be a potential therapeutic agent for CML treatment with a double effect, on cancer cells and on tumor microenvironment [22]. Numerous papers documented the protective effects of curcumin in leukemia malignancy.…”

Liquid biopsy - emergence of a new era in personalized cancer care

“…In another published case report, a 70 year old woman with no relevant past medical history diagnosed with stage IV NSCLC, (adenocarcinoma histotype) was found to harbor an Del19 EGFR activating mutation in her exosome DNA. The patient was treated with Gefitinib and was found to respond to the treatment with stabilization of disease and an improvement in quality of her life within 10 months [165].…”